TY - JOUR AU - Lavacchi, Daniele AU - Mini, Enrico AU - Roviello, Giandomenico PY - 2019 TI - Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? JF - AME Medical Journal; Vol 4 (April 2019): AME Medical Journal Y2 - 2019 KW - N2 - Khalaf et al . (1) presented a sub-sequent analysis of a previously conducted phase II trial aimed to compare activity of abiraterone acetate + prednisone (AA + P) versus enzalutamide (E) in more than 200 patients with treatment-naive metastatic castration-resistant prostate cancer (2). In this study, the authors found that AA + P and E showed similar activity in terms of time to prostate-specific antigen (PSA), clinical, or radiographic progression (2). UR - https://amj.amegroups.org/article/view/4923